Mesenchymal Stem Cell Transplantation in Liver Diseases

Area of Science:

• Hepatology and Regenerative Medicine
• Immunology and Cell Therapy

Background:

• Preclinical studies indicated bone marrow-derived mesenchymal stem cells (BM-MSCs) could reduce hepatic fibrosis, promote liver regeneration, and mitigate inflammation in acute-on-chronic liver failure (ACLF).
• Clinical trials in decompensated cirrhosis patients showed BM-MSC injections improved biochemical markers and survival in ACLF, primarily in hepatitis B virus-infected populations.
• Conflicting results from European studies highlight the need for further investigation into MSC efficacy and alternative therapeutic strategies for ACLF.

Purpose of the Study:

• To evaluate the potential of mesenchymal stem cells (MSCs) and related therapies in managing acute-on-chronic liver failure (ACLF).
• To explore alternative approaches such as granulocyte colony-stimulating factor (G-CSF) and liver-derived progenitor cells for ACLF treatment.
• To investigate the paracrine mechanisms and anti-inflammatory effects of human allogeneic liver-derived MSCs in liver disease.

Main Methods:

• Review of preclinical data on bone marrow-derived mesenchymal stem cells (BM-MSCs) for hepatic fibrosis and regeneration.
• Analysis of clinical studies involving BM-MSC injections in patients with decompensated cirrhosis and ACLF.
• Examination of research on granulocyte colony-stimulating factor (G-CSF) and human allogeneic liver-derived MSCs as potential ACLF treatments.

Main Results:

• Preclinical data suggest BM-MSCs possess therapeutic potential for liver regeneration and inflammation reduction in ACLF.
• Clinical studies reported survival benefits and improved liver function with BM-MSC therapy in some ACLF patient groups, but European trials failed to replicate these findings.
• G-CSF and liver-derived MSCs are being investigated as alternatives, with some studies showing promise but requiring further validation, particularly in European cohorts.

Conclusions:

• The efficacy of BM-MSC therapy for ACLF remains controversial, with inconsistent results between different study populations and geographical regions.
• Granulocyte colony-stimulating factor (G-CSF) and human allogeneic liver-derived MSCs represent promising alternative avenues for ACLF treatment, warranting further clinical investigation.
• Understanding the immunomodulatory and paracrine mechanisms of these cell-based therapies is crucial for optimizing their application in liver failure patients.